Development of 177Lu-nanobodies for radioimmunotherapy of HER2-positive breast cancer: Evaluation of different bifunctional chelators

Contrast Media and Molecular Imaging

Volumn 7, Issue 2, 2012, Pages 254-264

  D'Huyvetter, Matthias ^a,b   Aerts, An ^a   Xavier, Catarina ^b   Vaneycken, Ilse ^b   Devoogdt, Nick ^b   Gijs, Marlies ^a   Impens, Nathalie ^a   Baatout, Sarah ^a   Ponsard, Bernard ^a   Muyldermans, Serge ^b,c   Caveliers, Vicky ^b,d   Lahoutte, Tony ^b,d  

^a BELGIAN NUCLEAR RESEARCH CENTRE   (Belgium)

^b VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^c DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^d UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Bifunctional chelator; Breast cancer; HER2; Lutetium 177; Nanobody

Indexed keywords

CHELATING AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LUTETIUM 177; NANOBODY; NANOPARTICLE; PENTETIC ACID; RADIOISOTOPE; TETRAXETAN; UNCLASSIFIED DRUG; 2 (4 ISOTHIOCYANATOBENZYL) 6 METHYLDIETHYLENETRIAMINEPENTAACETIC ACID; 2-(4-ISOTHIOCYANATOBENZYL)-6-METHYLDIETHYLENETRIAMINEPENTAACETIC ACID; DIAGNOSTIC AGENT; DRUG DERIVATIVE; LUTETIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG STABILITY; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION DOSE; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; BREAST TUMOR; FEMALE; IMMUNOLOGY; KINETICS; METABOLISM; METHODOLOGY; SCINTISCANNING; TIME; TISSUE DISTRIBUTION; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CHELATING AGENTS; FEMALE; HUMANS; KINETICS; LUTETIUM; MALE; MICE; NANOPARTICLES; PENTETIC ACID; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RECEPTOR, ERBB-2; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 84858726520     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.491     Document Type: Article

References (27)

1. Olayioye MA. Intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res 2001; 3: 285-389.
2. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005; 5: 341-335.
3. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61(suppl 2): 1-13.
4. Hicks DG, Kulkarni S. HER2 breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol 2008; 129: 263-273.
5. Agus DB, Gordon MS, Taylor C, Natale RB, Karlan B, Mendelson DS, Kelsey SM, Fyfe G. Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. J Clin Oncol 2005; 23: 2534-2543.
6. Ignatiadis M, Desmedt C, Sotiriou C, de Azambuja E, Piccart M. HER-2 as a target for breast cancer therapy. Clin Cancer Res 2009; 15(6): 1848-1852.
7. Baselga J. Clinical trials of Herceptin (trastuzumab). Eur J Cancer 2001; 37(suppl 1): 18-24.
8. Piccart M. Circumventing de novo and acquired resistance to trastuzumab: new hope for the care of ErbB2-positive breast cancer. Clin Breast Cancer 2008; 8(suppl 3): S100-S113.
9. Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 2007; 77: 13-22.
10. Vaneycken I, Devoogdt N, Van Gassen N, Vincke C, Xavier C, Wernery U, Muyldermans S, Lahoutte T, Caveliers V. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J 2011; 25: 2433-2446.
11. Hummet JL. Dosimetric aspects of radiolabeled antibodies for tumor therapy. J Nucl Med 1986; 27: 1490-1497.
12. Cutler CS, Smith CJ, Ehrhardt GJ, Tyler TT, Jurisson SS, Deutsch E. Current and potential therapeutic uses of lanthanide radioisotopes. Cancer Biother Radiopharm 2000; 15: 531-545.
13. 177Lu for radioimmunotherapeutic applications. Nucl Med Biol 2002; 29(4): 431-442.
14. 177Lu: in vivo comparison of macrocyclic and acyclic ligands. J Nucl Med Biol 2007; 34: 173-183.
15. 177Lu: in vivo comparison of marcocyclic and acyclic ligands. J Nucl Med Biol 2010; 37: 741-750.
16. Early Breast Cancer Trialists' Collaborative group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 265(9472): 1687.
17. 177Lu-labeled HER2-specific affibody molecule. Cancer Res 2007; 67(6): 2773-2782.
18. Tijink BM, Laeremans T, Budde M, Stigter-van Walsum T, Dreier T, de Haard HJ, Leemans CR, van Dongen GAMS. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther 2008; 7(8): 2288-2297.
19. Tolmachev V. Imaging of HER-2 Overexpression in tumors for guiding therapy. Curr Pharm Des 2008; 14: 2999-3019.
20. Rasaneh S, Rajabi H, Babaei MH, Daha FJ. Synthesis and biodistribution studies of 177Lu-trastuzumab as a therapeutic agent in the breast cancer mice model. J Label Compd Radiopharm 2010; 53: 575-579.
21. Melis M, Bijster M, de Visser M, Konijnenberg MW, de Swart J, Rolleman EJ, Boerman OC, Krenning EP, de Jong M. Dose-response effect of Gelofusine on renal uptake and retention of radiolabelled octreotide in rats with CA20948 tumours. Eur J Med Mol Imag 2009; 36: 1968-1976.
22. Christensen EL, Brin H. Megalin and cubulin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol 2002; 3: 256-266.
23. De Jong M, Barone R, Krenning E, Bernard B, Melis M, Visser T, Gekle M, Willnow TE, Walrand S, Jamar F, Pauwels S. Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide. J Nucl Med 2005; 46: 1696-1700.
24. 111In-octreotide in mice and rats. J Nucl Med 2006; 47: 528-533.
25. Tchouate G, Caveliers V, Devoogdt N, Vanhove C, Xavier C, Boerman O, Muyldermans S, Bossuyt A, Lahoutte T. Localization, mechanism and reduction of renal retention of technetium-99m labeled epidermal growth factor receptor-specific nanobody in mice. Contrast Media Mol Imag 2011; 6: 85-92.
26. 99mTc-labeled recombinant affibody molecule improves their biodistribution and imaging properties. J Nucl Med 2011; 52: 461-469.
27. Vaneycken I, Xavier C, Blykers A, Devoogdt N, Caveliers V, Lahoutte T. Synthesis and first in vivo evaluation of 18F-anti-HER2-nanobodies: a new probe for PET imaging of HER2 expression in breast cancer. [Abstract.] J Nucl Med 2011; 52: 6.